{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:03:03Z","timestamp":1766023383816,"version":"3.48.0"},"reference-count":23,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/wqyo9624","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T04:21:39Z","timestamp":1737519699000},"page":"162-177","source":"Crossref","is-referenced-by-count":0,"title":["Delta\/pre-radiomics based on enhanced CT predicts complete response in locally advanced esophageal squamous cell carcinoma"],"prefix":"10.62347","volume":"17","author":[{"given":"Yan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"718","DOI":"10.21037\/jtd-22-1789","article-title":"Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial)","volume":"15","author":"Yin","year":"2023","unstructured":"Yin J, Lin S, Fang Y, Jiao H, Chen Z, Tang H, Gu J, Zhang S, Sun L, Li Y, Han Y, Chen Q, Chen H, Li Z and Tan L. Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). J Thorac Dis 2023; 15: 718-730.","journal-title":"J Thorac Dis"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2013.0009","article-title":"Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers","volume":"11","author":"VE","year":"2013","unstructured":"Strong VE, D’Amico TA, Kleinberg L and Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw 2013; 11: 60-66.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1245\/s10434-022-12752-1","article-title":"Efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma: a meta-analysis","volume":"30","author":"Xu","year":"2023","unstructured":"Xu J, Yan C, Li Z, Cao Y, Duan H and Ke S. Efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma: a meta-analysis. Ann Surg Oncol 2023; 30: 1597-1613.","journal-title":"Ann Surg Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","unstructured":"Tang H, Wang H, Fang Y, Zhu JY, Yin J, Shen YX, Zeng ZC, Jiang DX, Hou YY, Du M, Lian CH, Zhao Q, Jiang HJ, Gong L, Li ZG, Liu J, Xie DY, Li WF, Chen C, Zheng B, Chen KN, Dai L, Liao YD, Li K, Li HC, Zhao NQ and Tan LJ. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol 2023; 34: 163-172.","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.21873\/invivo.13025","article-title":"Prognostic factors for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery","volume":"36","author":"Kitasaki","year":"2022","unstructured":"Kitasaki N, Hamai Y, Emi M, Kurokawa T, Yoshikawa T, Hirohata R, Ohsawa M and Okada M. Prognostic factors for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. In Vivo 2022; 36: 2852-2860.","journal-title":"In Vivo"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.21037\/jtd-20-1088","article-title":"The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma","volume":"12","author":"Park","year":"2020","unstructured":"Park SY, Hong MH, Kim HR, Lee CG, Cho JH, Cho BC and Kim DJ. The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. J Thorac Dis 2020; 12: 6426-6434.","journal-title":"J Thorac Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.xjon.2021.11.003","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: trial design","volume":"9","author":"Zheng","year":"2022","unstructured":"Zheng Y, Li C, Yu B, Zhao S, Li J, Chen X and Li H. Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: trial design. JTCVS Open 2022; 9: 293-299.","journal-title":"JTCVS Open"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1118902","DOI":"10.3389\/fimmu.2023.1118902","article-title":"The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis","volume":"14","author":"He","year":"2023","unstructured":"He W, Wang C, Li C, Nie X, Li H, Li J, Zhao N, Chen H, Miao X, Han Y, Peng L and Leng X. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. Front Immunol 2023; 14: 1118902.","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00428-022-03340-5","article-title":"Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case-control study","volume":"481","author":"Helminen","year":"2022","unstructured":"Helminen O, Melkko J, Saarnio J, Sihvo E, Kuopio T, Ohtonen P, Kauppila JH, Karttunen TJ and Huhta H. Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett’s esophagus: a matched case-control study. Virchows Arch 2022; 481: 467-476.","journal-title":"Virchows Arch"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/01.pas.0000213312.36306.cc","article-title":"Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome","volume":"31","author":"TT","year":"2007","unstructured":"Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA and Swisher SG. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 2007; 31: 58-64.","journal-title":"Am J Surg Pathol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/PAS.0000000000000255","article-title":"Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches","volume":"38","author":"Karamitopoulou","year":"2014","unstructured":"Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K and Langer R. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. Am J Surg Pathol 2014; 38: 1551-1556.","journal-title":"Am J Surg Pathol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","article-title":"Japanese classification of esophageal cancer, 11th edition: part I","volume":"14","author":"Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus 2017; 14: 1-36.","journal-title":"Esophagus"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1038\/ajg.2009.437","article-title":"Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case-control study","volume":"104","author":"Sikkema","year":"2009","unstructured":"Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD and Kuipers EJ. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case-control study. Am J Gastroenterol 2009; 104: 2673-2680.","journal-title":"Am J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1131883","DOI":"10.3389\/fonc.2023.1131883","article-title":"Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery","volume":"13","author":"Li","year":"2023","unstructured":"Li K, Li Y, Wang Z, Huang C, Sun S, Liu X, Fan W, Zhang G and Li X. Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery. Front Oncol 2023; 13: 1131883.","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1186\/s12885-021-08899-x","article-title":"Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive radiomic biomarkers","volume":"21","author":"Zhu","year":"2021","unstructured":"Zhu Y, Yao W, Xu BC, Lei YY, Guo QK, Liu LZ, Li HJ, Xu M, Yan J, Chang DD, Feng ST and Zhu ZH. Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive radiomic biomarkers. BMC Cancer 2021; 21: 1167.","journal-title":"BMC Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1131883","DOI":"10.3389\/fonc.2023.1131883","article-title":"Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery","volume":"13","author":"Li","year":"2023","unstructured":"Li K, Li Y, Wang Z, Huang C, Sun S, Liu X, Fan W, Zhang G and Li X. Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery. Front Oncol 2023; 13: 1131883.","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P and Kato K. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398: 759-771.","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2217\/fon-2018-0609","article-title":"KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer","volume":"15","author":"Kato","year":"2019","unstructured":"Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Özgüroğlu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S and Doi T. KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol 2019; 15: 1057-1066.","journal-title":"Future Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J and Xu RH. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 2021; 326: 916-925.","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/01635581.2022.2123533","article-title":"Peripheral blood markers predictive of progression-free survival in advanced esophageal squamous cell carcinoma patients treated with PD-1 inhibitors plus chemotherapy as first-line therapy","volume":"75","author":"Chen","year":"2023","unstructured":"Chen W, Li D, Bian X, Wu Y, Xu M, Wu M and Tao M. Peripheral blood markers predictive of progression-free survival in advanced esophageal squamous cell carcinoma patients treated with PD-1 inhibitors plus chemotherapy as first-line therapy. Nutr Cancer 2023; 75: 207-218.","journal-title":"Nutr Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10388-023-01005-z","article-title":"Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery","volume":"20","author":"Tanishima","year":"2023","unstructured":"Tanishima Y, Takahashi K, Nishikawa K, Ishikawa Y, Yuda M, Tanaka Y, Matsumoto A, Yano F and Eto K. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery. Esophagus 2023; 20: 651-659.","journal-title":"Esophagus"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00259-020-04955-z","article-title":"Hybrid PET\/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review","volume":"48","author":"Dahlsgaard-Wallenius SE","year":"2021","unstructured":"Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, Vilstrup MH, Petersen H, Gerke O, Høilund-Carlsen PF, Morsing A and Andersen TL. Hybrid PET\/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review. Eur J Nucl Med Mol Imaging 2021; 48: 584-591.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"12003","DOI":"10.2147\/OTT.S261068","article-title":"Pretreatment CT-based radiomics signature as a potential imaging biomarker for predicting the expression of PD-L1 and CD8+TILs in ESCC","volume":"13","author":"Wen","year":"2020","unstructured":"Wen Q, Yang Z, Zhu J, Qiu Q, Dai H, Feng A and Xing L. Pretreatment CT-based radiomics signature as a potential imaging biomarker for predicting the expression of PD-L1 and CD8+TILs in ESCC. Onco Targets Ther 2020; 13: 12003-12013.","journal-title":"Onco Targets Ther"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/1\/ajtr0157190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:07Z","timestamp":1766023087000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/1\/ajtr0157190.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/wqyo9624","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2025]]}}}